<DOC>
	<DOCNO>NCT00272779</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability antiviral effect atazanavir ( ATV ) plus ritonavir ( RTV ) versus combination drug lopinavir ( LPV ) plus RTV . A combination drug contain tenofovir ( TDF ) emtricitabine ( FTC ) also take participant arm .</brief_summary>
	<brief_title>BMS-Reyataz Study Treatment Naive Subjects Compare Efficacy Safety Between Boosted Reyataz Kaletra When Combination With Fixed Dose Truvada</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>HIV RNA ≥5000 c/ml Any antiretroviral therapy within 30 day prior screen ; Women Childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study 8 week study ; WOCBP use prohibit contraceptive method WOCBP pregnant breastfeeding ; Women positive pregnancy test enrollment prior study drug administration ; Presence newly diagnose HIVRelated opportunistic infection medical condition require acute therapy time enrollment ; Suspected primary ( acute ) HIV infection ; Prior antiviral therapy ( &gt; 30 day NRTI and/or &gt; 7 day nonnucleoside reverse transcriptase inhibitor ( NNRTI ) PI therapy ) antiretroviral therapy within 30 day prior screen ; exception allow ARV therapy use Mothertochild transmission ; Participants Cushing 's syndrome ; Untreated hypothyroidism hyperthyroidism . A participant euthyroid stable replacement dose thyroid hormone acceptable provide thyroid stimulate hormone ( TSH ) perform within 30 day screen within normal drug range ; Recent therapy agent significant systemic myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic cytotoxic potential within 3 month study start expect need therapy time enrollment ; therapy methadone ribavirin/interferons treatment neurotoxic drug drug affect CYP3A4 ; Participants obstructive liver disease ; Active alcohol substance use sufficient , Investigator 's opinion , prevent adequate compliance study therapy increase risk develop pancreatitis chemical hepatitis ; Proven suspect acute hepatitis 30 day prior study entry ; Intractable diarrhea ( ≥6 loose stools/day least 7 consecutive day ) within 30 day prior study entry ; Inability swallow capsule ; Active peripheral neuropathy ; Presence cardiomyopathy ( due cause ) significant cardiovascular disease , unstable ischemic heart disease ; Known , clinically significant cardiac conduction system disease . Baseline laboratory value measure within 2 week prior initiate study drug follow : 1. calculate creatine clearance &lt; 60 mL/min estimate CockcroftGault equation ; 2. total serum lipase ≥ 1.4 time upper limit normal ; 3. liver enzyme ( AST , ALT ) ≥ 5 time upper limit normal ; 4. total serum bilirubin ≥ 1.5 time upper limit normal . Hypersensitivity component formulation study drug ; Prohibited therapy ; Any clinical condition prior therapy , opinion Investigator , would make participant unsuitable study unable comply dose requirement ; Prisoners participant compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>